Brainsway plans to hold the offering by the end of May. The company will be traded under the ticker "BRIN". Maxim Group LLC and Roth Capital Ltd. are the underwriters.
Last week, Brainsway obtained EU CE Mark to use Deep TMS for the treatment of Parkinson's disease and as a supplemental treatment for patients taking antidepressants. The company is also conducting clinical trials of the device for treatment cocaine, smoking and other addictions, autism and Asperger's syndrome, and other neurological problems.
Brainsway's share price rose 1.2% by early afternoon to NIS 8.67, giving a market of NIS 406 million.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments